SARS-CoV-2 Antibody responses in end-stage renal disease patients after COVID-19 Vaccinatio

• Conditions: End-stage renal disease patients with renal replacement therapy receiving COVID-19 vaccine; ESRD; End stage kidney disease; COVID-19; SARS-CoV-2; Vaccine; RRT; Renal replacement therapy

• Registration Number: TCTR20210510009
• Lead Sponsor: Bamrasnaradura Infectious Diseases Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-05-10
• Study Completion: 2022-01-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

1. Age 18 years or more
2. End stage renal disease patients with renal replacement therapy visiting out-patient department
3. Eligible for COVID-19 vaccination
4. Informed consented for participation

Exclusion Criteria

1. Allergy to component in COVID-19 vaccine
2. Diagnosed with COVID-19 infection
3. Contraindicated for COVID-19 vaccine
4. On immunosuppressant

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
SARS-CoV-2 Antibody Before vaccination (Day 0), 5 and 10 weeks after first dose vaccination, 5 and 10 weeks after second dose vaccination ELISA, In vitro microneutralization assay, Rapid IgG/IgM Antibody Test Kit

Secondary Outcome Measures

Name	Time	Method
/A N/A N/A